A new DNA test could help screen whether patients require the treatment or not, according to a new international trial.
Trending
- Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma
- Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer
- Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma
- SETD8-mediated mono-methylation of YAP at K76 promotes K48-linked polyubiquitination and degradation to suppress colorectal cancer
- Weighing the Catabolic Effects of Lenvatinib/Everolimus vs SOC in ccRCC
- How Did KRAS Become an Actionable Target in Oncology?
- Tumor-derived annexin A1 drives lenvatinib resistance by regulating SOX2/STAT3/S100A6 feedback loop and M2 macrophage polarization in hepatocellular carcinoma
- How “Missing the Boat” Led Me Somewhere Better

